{"id":606987,"date":"2024-02-01T20:00:05","date_gmt":"2024-02-01T17:00:05","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/single-dose-dengue-vaccine-protects-79-6-of-those-vaccinated-study-shows\/"},"modified":"2024-02-01T20:00:05","modified_gmt":"2024-02-01T17:00:05","slug":"single-dose-dengue-vaccine-protects-79-6-of-those-vaccinated-study-shows","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/single-dose-dengue-vaccine-protects-79-6-of-those-vaccinated-study-shows\/","title":{"rendered":"#Single-dose dengue vaccine protects 79.6% of those vaccinated, study shows"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a40b140ca34a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #dd3333;color:#dd3333\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #dd3333;color:#dd3333\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a40b140ca34a\" checked aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/buradabiliyorum.com\/en\/single-dose-dengue-vaccine-protects-79-6-of-those-vaccinated-study-shows\/#Secondary_benefits\" >Secondary benefits<\/a><\/li><\/ul><\/nav><\/div>\n<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2024\/butantan-institutes-de.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/2024\/butantan-institutes-de.jpg\" data-sub-html=\"Batch used to validate the vaccine's production process at the Butantan Institute. Credit: Andr\u00e9 Ricoy\/Comunica\u00e7\u00e3o Butantan\">\n<figure class=\"article-img\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/scx1.b-cdn.net\/csz\/news\/800a\/2024\/butantan-institutes-de.jpg\" alt=\"Butantan Institute's dengue vaccine protects 79.6% of those vaccinated, study shows\" title=\"Batch used to validate the vaccine's production process at the Butantan Institute. Credit: Andr\u00e9 Ricoy\/Comunica\u00e7\u00e3o Butantan\" width=\"800\" height=\"530\"\/><figcaption class=\"text-darken text-low-up text-truncate-js text-truncate mt-3\">\n                Batch used to validate the vaccine&#8217;s production process at the Butantan Institute. Credit: Andr\u00e9 Ricoy\/Comunica\u00e7\u00e3o Butantan<br \/>\n            <\/figcaption><\/figure>\n<\/div>\n<\/div>\n<p>A single-dose dengue vaccine produced by Butantan Institute in S\u00e3o Paulo state (Brazil) prevents development of the disease in 79.6% of those vaccinated, according to an <a rel=\"nofollow noopener\" target=\"_blank\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301790?query=featured_home\">article<\/a> published in <i>The New England Journal of Medicine<\/i>.<\/p>\n<p>                                                                                                                                    Called Butantan-DV, the vaccine contains attenuated versions of all four dengue virus serotypes. The results of the ongoing Phase 3 trial show that it is safe and effective for all age groups between 2 and 59, and for people with or without a prior history of infection by dengue virus.<\/p>\n<p>&#8220;Publication of the article in the world&#8217;s leading medical journal attests to the rigor and quality of the work done by researchers at 16 Brazilian centers located in all five regions of the country, and coordinated by Butantan Institute,&#8221; infectious disease specialist Esper Kall\u00e1s, first author of the article, told Ag\u00eancia FAPESP. &#8220;In June, we&#8217;ll complete the five-year follow-up period. Once the data has been consolidated, we&#8217;ll know how long the protection induced by the vaccine will last.&#8221;<\/p>\n<p>Also according to Kall\u00e1s, who heads Butantan Institute, the researchers plan to submit a report to ANVISA, Brazil&#8217;s health surveillance agency, in the second half of this year in order to <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/download-scripts-themes-apps\/\" data-internallinksmanager029f6b8e52c=\"9\" title=\"Download Scripts &amp; Themes &amp; Apps\" target=\"_blank\" rel=\"noopener\">app<\/a>ly for registration of the vaccine.<\/p>\n<p>&#8220;If all goes well, we&#8217;ll win definitive approval for the vaccine in 2025. We already have the infrastructure to produce it at Butantan Institute, although it can still be perfected. After all, it&#8217;s tetravalent, corresponding to four vaccines in one,&#8221; he said.<\/p>\n<p>                                                                                                        <!-- Google middle Adsense block --><\/p>\n<p>                                                                                                                                            The article published today describes the results of the first two years of the Phase 3 clinical trial, which began in February 2016 and involves 16,235 participants in 13 states. Preliminary data disclosed by Butantan Institute in December 2022 pointed to overall efficacy of 79.6%. The results for each subgroup evaluated have now been detailed.<\/p>\n<p>Vaccine efficacy was 80.1% for participants aged 2-6, 77.8% for those aged 7-17, and 90.0% for 18-59 age group. Stratification by serological status showed protection for 73.6% of participants with no evidence of prior infection by dengue virus and 89.2% of those previously exposed to the virus. Efficacy was 89.5% against dengue serotype 1 (DENV-1) and 69.6% against serotype 2 (DENV-2).<\/p>\n<p>It was not possible to assess the vaccine&#8217;s efficacy against serotypes 3 and 4 because they were not circulating during the follow-up period. Most adverse side effects were classified as mild or moderate. The main reactions were pain and redness at the injection site, headache, and fatigue. Severe adverse events relating to the vaccine were recorded for under 0.1% of all those vaccinated, and all of them recovered.<\/p>\n<p>&#8220;Findings from Phase 2 [the previous clinical trial] showed that the four attenuated viral serotypes in Butantan-DV multiply in the human organism and induce a balanced response in terms of antibody production. This leads us to conclude that its efficacy against DENV-3 and DENV-4 will also be good,&#8221; said virologist Maur\u00edcio Lacerda Nogueira, one of the coordinators of the trials.<\/p>\n<p>                                                                                                                                            &#8220;It should be stressed that Butantan Institute&#8217;s vaccine has also proved extremely safe for people who have never had dengue, which is an advantage over the vaccines now available on the market. Furthermore, it can be administered to a broader age group and a single dose is sufficient.&#8221; Nogueira is a professor at the S\u00e3o Jos\u00e9 do Rio Preto Medical School (FAMERP), one of the centers that are running the trials.<\/p>\n<p>Two dengue vaccines have been approved in Brazil to date. One is Dengvaxia, produced by Sanofi Pasteur. This vaccine requires three applications and is indicated for people aged 9\u201345 who have had dengue. The other is Qdenga, produced by Takeda. Application in Brazil will begin this month, for people aged 4\u201360, regardless of serological status. Two doses will be needed for full immunization in this case.<\/p>\n<p>Butantan-DV&#8217;s single-dose scheme has several advantages, the authors write in the article. In addition to the logistical and economic benefits, rapid protection may be important in the event of an outbreak and for <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/trip-and-travel\/\" data-internallinksmanager029f6b8e52c=\"10\" title=\"Trip &amp; Travel\" target=\"_blank\" rel=\"noopener\">travel<\/a>ers without immunity to places where the disease is endemic.<\/p>\n<p>In Brazil, dengue is considered hyperendemic, meaning its high prevalence remains constant from one year to the next. According to the Health Ministry, 1.6 million probable cases were notified in the first 11 months of 2023. So far this year, the number of probable cases has reached 217,841, according to data disclosed on Tuesday, January 30. Fifteen deaths have been confirmed, and 149 are under investigation. Based on these numbers, the current incidence rate in Brazil is calculated as 107.1 cases per 100,000 inhabitants, and the fatality rate is 0.9%.<\/p>\n<p>                                                                                                        <!-- Google middle Adsense block --><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Secondary_benefits\"><\/span>Secondary benefits<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Development of the tetravalent dengue vaccine began at Butantan Institute in 2010, using a formulation created by researchers affiliated with the US National Institutes of Health (NIH). Clinical trials in Brazil began in 2013, under the aegis of the project &#8220;Development of a tetravalent dengue vaccine,&#8221; led by Neuza Frazatti Gallina, winner of the 2023 P\u00e9ter Mur\u00e1nyi Prize. The Phase 3 trial, which is set to end in June, may be the largest clinical trial of a vaccine ever conducted solely in Brazil.<\/p>\n<p>&#8220;The cost of dengue in Brazil is absurd,&#8221; Nogueira said. &#8220;The vaccine is expected to reduce mortality and hospitalizations due to the disease, so investment of several hundred million reais by the Brazilian government in the development of an indigenous vaccine will have a huge impact on public health.<\/p>\n<p>&#8220;Secondary benefits can already be observed. The scientists in charge of the trial reported in the article conducted clinical trials of CoronaVac during the COVID-19 pandemic. So we were prepared. Formation of this vaccine research network is a valuable achievement that the Brazilian government must preserve. It will enable us to respond rapidly to future challenges of a similar kind.&#8221;<\/p>\n<div class=\"article-main__more p-4\">\n                                                                                                    <strong>More information:<\/strong><br \/>\n                                                    Esper G. Kall\u00e1s et al, Live, Attenuated, Tetravalent Butantan\u2013Dengue Vaccine in Children and Adults, <i>New England Journal of Medicine<\/i> (2024). <a rel=\"nofollow noopener\" target=\"_blank\" data-doi=\"1\" href=\"https:\/\/dx.doi.org\/10.1056\/NEJMoa2301790\">DOI: 10.1056\/NEJMoa2301790<\/a><\/p>\n<\/div>\n<p>                                        <!-- print only --><\/p>\n<div class=\"d-none d-print-block\">\n<p>                                                 <strong>Citation<\/strong>:<br \/>\n                                                 Single-dose dengue vaccine protects 79.6% of those vaccinated, study shows (2024, February 1)<br \/>\n                                                 retrieved 1 February 2024<br \/>\n                                                 from https:\/\/medicalxpress.com\/<a href=\"https:\/\/buradabiliyorum.com\/en\/category\/news\/\" data-internallinksmanager029f6b8e52c=\"2\" title=\"News\" target=\"_blank\" rel=\"noopener\">news<\/a>\/2024-02-dose-dengue-vaccine-vaccinated.html<\/p>\n<p>                                            This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no<br \/>\n                                            part may be reproduced without the written permission. The content is provided for information purposes only.<\/p><\/div>\n<\/p><\/div>\n<p><script id=\"facebook-jssdk\" async=\"\" src=\"https:\/\/connect.facebook.net\/en_US\/sdk.js\"><\/script><\/p>\n<blockquote><p><strong><span style=\"color: #ff6600;\">If you liked the article, do not forget to share it with your friends. Follow us on\u00a0<span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN63nwsw68G3Aw\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\"><strong>If you want to read more Like this articles, you can visit our <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/en.buradabiliyorum.com\/science\/\" target=\"_blank\" rel=\"noopener\">Science category.<\/a><\/span><\/strong>\n<\/p><\/blockquote>\n<p><span style=\"color: black;\"><a style=\"color: #ff9900;\" href=\"https:\/\/medicalxpress.com\/news\/2024-02-dose-dengue-vaccine-vaccinated.html\" target=\"_blank\" rel=\"noopener\">Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Batch used to validate the vaccine&#8217;s production process at the Butantan Institute. Credit: Andr\u00e9 Ricoy\/Comunica\u00e7\u00e3o Butantan A single-dose dengue vaccine produced by Butantan Institute in S\u00e3o Paulo state (Brazil) prevents development of the disease in 79.6% of those vaccinated, according to an article published in The New England Journal of Medicine. Called Butantan-DV, the vaccine&#8230;<\/p>\n","protected":false},"author":1,"featured_media":606988,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/scx2.b-cdn.net\/gfx\/news\/2024\/butantan-institutes-de.jpg","fifu_image_alt":"","footnotes":""},"categories":[16],"tags":[],"class_list":["post-606987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciencee"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/606987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=606987"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/606987\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/606988"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=606987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=606987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=606987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}